دورية أكاديمية
Efficacy and safety of tenofovir, entecavir, and telbivudine for chronic hepatitis B in heart transplant recipients
| العنوان: | Efficacy and safety of tenofovir, entecavir, and telbivudine for chronic hepatitis B in heart transplant recipients |
|---|---|
| المؤلفون: | DURANTE MANGONI, Emanuele, UTILI, Riccardo, ZAMPINO, Rosa, Vitrone, M, Parrella, A, Andini, R, Iossa, D, Ragone, E, Falco, E, Maiello, C |
| المساهمون: | DURANTE MANGONI, Emanuele, Vitrone, M, Parrella, A, Andini, R, Iossa, D, Ragone, E, Falco, E, Maiello, C, Utili, Riccardo, Zampino, Rosa |
| بيانات النشر: | Blackwell Publishing Inc. HOBOKEN 111 RIVER ST, HOBOKEN 07030-5774, NJ USA |
| سنة النشر: | 2016 |
| المجموعة: | Università degli Studi della Campania "Luigi Vanvitelli": CINECA IRIS V: |
| مصطلحات موضوعية: | antiviral, heart transplant, hepatitis B, safety |
| الوصف: | Background: Treatment of chronic hepatitis B (CHB) with polymerase inhibitors is key to prevent disease flares and progression toward advanced liver disease. Efficacy and tolerability of newer agents has been reported anecdotally in transplant recipients. Methods: In this prospective, observational study, we assessed outcomes of therapy with tenofovir (TDF), entecavir (ETV), and telbivudine (LdT) in 13 heart transplant recipients (HTR) with CHB. Results: Most patients were hepatitis B e antigen negative, had low baseline hepatitis B virus (HBV) DNA, and normal aminotransferases. Liver biopsy showed a median fibrosis score of 1.5 (range 0–4). Glomerular filtration rate (GFR) was <50 mL/min in 7 patients (54%). Two patients were started on de novo ETV before transplant. Eleven previously treated patients were switched to TDF (n = 9) or LdT (n = 2). Median treatment duration was 33 months (range 1–71). HBV DNA remained suppressed in 6 patients and became undetectable in 5. Aminotransferases went down to the normal range in all patients, with a single flare in 1 patient. One patient lost hepatitis B surface antigen. No cases occurred of hepatic decompensation, hepatocellular carcinoma, or liver-related death. The GFR remained largely stable, and no cases of TDF-related hyper-phosphaturia were observed. Conclusions: This study indicates that newer antivirals are effective and safe in HTR with CHB. |
| نوع الوثيقة: | article in journal/newspaper |
| اللغة: | English |
| العلاقة: | info:eu-repo/semantics/altIdentifier/pmid/26988401; info:eu-repo/semantics/altIdentifier/wos/WOS:000378721400001; volume:18; issue:3; firstpage:319; lastpage:325; numberofpages:7; journal:TRANSPLANT INFECTIOUS DISEASE; http://hdl.handle.net/11591/363530Test; info:eu-repo/semantics/altIdentifier/scopus/2-s2.0-84973925418; http://onlinelibrary.wiley.com/journal/10.1111Test/(ISSN)1399-3062 |
| DOI: | 10.1111/tid.12525 |
| DOI: | 10.1111/(ISSN)1399-3062 |
| الإتاحة: | https://doi.org/10.1111/tid.12525Test http://hdl.handle.net/11591/363530Test |
| رقم الانضمام: | edsbas.F7BF5C3C |
| قاعدة البيانات: | BASE |
| DOI: | 10.1111/tid.12525 |
|---|